| In a recent interview with the French site JOL Press, gerontologist Aubrey de Grey suggested that his SENS Foundation was very close to announcing a major breakthrough in a rejuvenation biotechnology for the prevention and mitigation of cardiovascular disease. |
SENS is an acronym for "Strategies for Engineered Negligible Senescence". The work at the SENS Foundation is described as an integrated set of medical techniques designed to restore youthful molecular and cellular structure to aged tissues and organs. Essentially, this involves the application of regenerative medicine to the problem of age-related sickness and disease.
Regenerative medicine is usually encompasses a few specific technologies such as stem cell therapy and tissue engineering, whereas SENS incorporates a variety of other techniques to remove or obviate the accumulating damage of aging. This broadly defined regenerative medicine - which includes the repair of living cells and extra-cellular material in situ - applied to damage of aging, is what the organization refers to as rejuvenation biotechnologies.
Now, in a recent interview with de Grey at the French site, JOL Press, the gerontologist commented:
He continues, "We are continuing our experiments. If all goes as we hope, we expect significant gains in the rats of 8 to 10 years, then apply to humans in 20 or 40 years."
Although mortality rates have declined in higher-income countries over the last two decades cardiovascular diseases remain the biggest cause of deaths worldwide. Moreover, cardiovascular deaths and disease are on the rise at a fast rate in low- and middle-income countries.
As soon as more information becomes available on SENS's work, we will let you know.
SOURCE JOL Press
We just received this note from the SENS Foundation:
Dear 33rd Square Team,
I just wanted to let you know that the French interview that served as the basis for your article on SENS and heart disease from January 3 (http://www.33rdsquare.com/2013/01/sens-foundation-close-to-breakthrough.html) appears to contain something of a mistranslation. When Dr. de Grey was discussing LysoSENS, he was referring to a recent publication generated by Rice University, which is discussed briefly on our website at http://sens.org/node/2990. These are very exciting results, and we’re looking forward to funding more of Dr. Mathieu’s work to generate further advances; any treatment that may come from this research is still years away, though. The science is progressing nicely, but there is no imminent breakthrough to be announced shortly.
Daniel Kimbel
Media Relations
SENS Foundation
Now, in a recent interview with de Grey at the French site, JOL Press, the gerontologist commented:
"One of our projects which we hope to make public soon, is a revolutionary advance to insert a gene in our patients from a bacteria and prevent them from dying from cardiovascular disease - the No. 1 cause of death today."
He continues, "We are continuing our experiments. If all goes as we hope, we expect significant gains in the rats of 8 to 10 years, then apply to humans in 20 or 40 years."
Although mortality rates have declined in higher-income countries over the last two decades cardiovascular diseases remain the biggest cause of deaths worldwide. Moreover, cardiovascular deaths and disease are on the rise at a fast rate in low- and middle-income countries.
SOURCE JOL Press
*NOTICE- January 7, 2013
We just received this note from the SENS Foundation:
Dear 33rd Square Team,
I just wanted to let you know that the French interview that served as the basis for your article on SENS and heart disease from January 3 (http://www.33rdsquare.com/2013/01/sens-foundation-close-to-breakthrough.html) appears to contain something of a mistranslation. When Dr. de Grey was discussing LysoSENS, he was referring to a recent publication generated by Rice University, which is discussed briefly on our website at http://sens.org/node/2990. These are very exciting results, and we’re looking forward to funding more of Dr. Mathieu’s work to generate further advances; any treatment that may come from this research is still years away, though. The science is progressing nicely, but there is no imminent breakthrough to be announced shortly.
Daniel Kimbel
Media Relations
SENS Foundation
We appreciate this feedback from the SENS Foundation and remain firm supporters of their important work.
| By 33rd Square | Subscribe to 33rd Square |
0 comments:
Post a Comment